02/06/2021 - 10:40

PharmAust targets Q4 for motor neuron disease clinical trial

02/06/2021 - 10:40

Bookmark

Save articles for future reference.

ASX-listed biotechnology company, PharmAust has secured Monash Health Human Research Ethics Committee approval for a Phase I clinical trial to assess the effectiveness of its monepantel product in combating motor neuron disease. Twelve trial participants will be tested in the fourth quarter this year. The trial has about A$880,000 of funding from charitable organisation, FightMND Australia.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options